Clinical Trial
Study Details
Low Dose Rifaximin Extended Release Twice Daily
Low Dose Rifaximin Delayed Extended Release Twice Daily
High Dose Rifaximin Extended Release Twice Daily
High Dose Rifaximin Delayed Extended Release Twice Daily
Placebo Twice Daily
This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs). Approximately 60 participants with sickle cell disease will be enrolled and randomized: 12 participants in each of four active novel formulation rifaximin groups and 6 participants in each of 2 placebo groups.
Study Overview
Contacts and Locations
Bausch Site 105
Orange, California 92868
United States
Bausch Site 103
Denver, Colorado 80220
United States
Bausch Site 104
Atlanta, Georgia 30329
United States
Bausch Site 101
Syracuse, New York 13210
United States
Bausch Site 102
Greenville, North Carolina 27834
United States
Bausch Site 201
Montreal Quebec H2X 3E4
Canada
Bausch Site 501
Eldoret
30100
Kenya
Bausch Site 502
Kisumu
40100
Kenya